疫苗开发不断变化的全球格局：Novotech 和 Endpoints News 网络研讨会
SYDNEY, AU, Feb 16, 2023 – (亚太商讯 via SEAPRWire.com) – Novotech 是领先的以亚太地区为中心的生物技术 CRO，在疫苗试验方面拥有丰富的经验，正在召开一次专家...
InaVac gets emergency approval from BPOM
Surabaya, East Java, Indonesia, Nov 14, 2022 – (ACN Newswire via SEAPRWire.com) – The Food and Drug Supervisory Agency (BPOM) has issued emergency use authorization (EUA) for InaVac, a COVID-19 vaccine developed by researchers from Airlangga University (Unair). InaVac, COVID-19 vaccine, is developed by the University of Airlangga in Surabaya, East Java Province. (ANTARA/HO-BPBRIN Unair)... » read more
AIM Vaccine Announces Proposed Listing on the Main Board of SEHK
HONG KONG, Sep 23, 2022 – (ACN Newswire via SEAPRWire.com) – AIM Vaccine Co., Ltd. (“AIM Vaccine” or the “Company”, together with its subsidiaries, the “Group”, stock code: 06660.HK), the second largest vaccine company in China in terms of 2021 approved lot release volume (excluding COVID-19 vaccines), announced the proposed listing of its H shares... » read more
Indonesia’s Bio Farma ready to produce ‘IndoVac’ Covid-19 vaccines
BANDUNG, INDONESIA, Sep 12, 2022 – (ACN Newswire via SEAPRWire.com) – PT Bio Farma, the holding company for state-owned pharmaceutical companies in Indonesia, announced a new milestone in manufacturing IndoVac, its Covid-19 vaccines brand, including primary series vaccines, booster vaccines and vaccines for children, in development since November 2021. IndoVac Covid-19 vaccine in production at... » read more
Indonesian pharmaceutical Bio Farma ready to produce IndoVac Covid-19 vaccines
Bandung, W Java, Indonesia, Sep 9, 2022 – (ACN Newswire via SEAPRWire.com) – PT Bio Farma, the holding company for state-owned pharmaceutical companies in Indonesia, announced a new milestone in the manufacturing of IndoVac, a Covid-19 vaccine brand it has developed since November 2021. IndoVac Covid-19 vaccine in production at PT Bio Farma’s facilities near... » read more
Toyota Announces Sales, Production, and Export Results for the First Half of 2022
Toyota City, Japan, Jul 28, 2022 – (JCN Newswire via SEAPRWire.com) – Toyota Motor Corporation (TMC) announces its sales, production, and export results for June 2022 as well as the cumulative total from January to June, including those for subsidiaries Daihatsu Motor Co., Ltd. and Hino Motors, Ltd. Highlights: In the first half of 2022,... » read more
Therapeutic Goods Administration Grants Provisional Approval for Moderna’s COVID-19 Vaccine in Children Aged Six Months to Five Years
Cambridge, MA, Jul 19, 2022 – (ACN Newswire via SEAPRWire.com) – Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic Goods Administration (TGA) in Australia has granted provisional registration for the use of Moderna’s mRNA COVID-19 vaccine, Spikevax, in a two-dose series of 25 ug per... » read more
Novotech Client SK bioscience Achieves SKYCovione(TM) COVID-19 Vaccine Approval in Korea
SEOUL, S.KOREA, Jul 13, 2022 – (ACN Newswire via SEAPRWire.com) – Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, congratulates its client SK bioscience on the recent COVID-19 vaccine licence approval. SK bioscience and GSK recently announced the successful authorization: SK bioscience announced that ‘SKYCovione(TM),’ South... » read more
V-01 as a Sequential Booster Can Produce Good Protection against Omicron —- Latest Phase III Data of COVID-19 Vaccine by Livzon Pharma
HONG KONG, Feb 18, 2022 – (ACN Newswire via SEAPRWire.com) – Global pandemic control is still facing enormous challenges after more than two years since the outbreak of the COVID-19. Following the Delta and Beta variants, Omicron variant emerged at the end of 2021, and its enhanced infectivity has cast a shadow over the global... » read more
Therapeutic Goods Administration of Australia Authorizes Moderna’s Covid-19 Vaccine in Children (6-11 Years)
Cambridge, MA, Feb 17, 2022 – (ACN Newswire via SEAPRWire.com) – Moderna, Inc., (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic Goods Administration (TGA) in Australia has granted provisional registration for the use of Moderna’s mRNA COVID-19 vaccine, Spikevax, in a 50 ug dose, two-dose series, for... » read more